NewcelX Ltd. (NCEL)
NewcelX Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Kloten, ZH, CH. The stock last traded at $3.21, up 0.78% on the session, giving a market capitalisation of $1.4M. On trailing twelve-month figures it carries a trailing P/E of -0.35, a net margin of 0.0%. Its beta of 0.93 implies it has historically moved less than the broad market.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
NewcelX Ltd. is most often compared with the following Healthcare names: